Cited 1 times since 2023 (0.8 per year) source: EuropePMC JACC. CardioOncology, Volume 5, Issue 1, 21 3 2023, Pages 117-127 Impact of Age at Diagnosis on Cardiotoxicity in High-Grade Osteosarcoma and Ewing Sarcoma Patients. Heemelaar JC, Speetjens FM, Al Jaff AAM, Evenhuis RE, Polomski EAS, Mertens BJA, Jukema JW, Gelderblom H, van de Sande MAJ, Antoni ML


Osteosarcoma and Ewing sarcoma patients face a significant risk of cardiotoxicity as defined by left ventricular dysfunction and heart failure (HF).


This study sought to evaluate the association between age at sarcoma diagnosis and incident HF.


A retrospective cohort study was performed at the largest sarcoma center in the Netherlands among patients with an osteosarcoma or Ewing sarcoma. All patients were diagnosed and treated over a 36-year period (1982-2018) and followed until August 2021. Incident HF was adjudicated through the universal definition of heart failure. Determinants including age at diagnosis, doxorubicin dose, and cardiovascular risk factors were entered as fixed or time-dependent covariates into a cause-specific Cox model to assess their impact on incident HF.


The study population consisted of 528 patients with a median age at diagnosis of 19 years (Q1-Q3: 15-30 years). Over a median follow-up time of 13.2 years (Q1-Q3: 12.5-14.9 years), 18 patients developed HF with an estimated cumulative incidence of 5.9% (95% CI: 2.8%-9.1%). In a multivariable model, age at diagnosis (HR: 1.23; 95% CI: 1.06-1.43) per 5-year increase, doxorubicin dose per 10-mg/m2 increase (HR: 1.13; 95% CI: 1.03-1.24), and female sex (HR: 3.17; 95% CI: 1.11-9.10) were associated with HF.


In a large cohort of sarcoma patients, we found that patients diagnosed at an older age are more prone to develop HF.

JACC CardioOncol. 2023 2;5(1):117-127